BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 150858)

  • 1. A method using fibrin-fixed Blue Dextran for determining the plasmin and plasmin inhibitor activities in human plasma.
    Tamura Y; Otsuka A; Sone K; Sakurai E; Mori H; Sumi H; Kosugi T; Fujii S
    Biochim Biophys Acta; 1978 Jul; 525(1):194-9. PubMed ID: 150858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin.
    Moroz LA; Gilmore NJ
    Blood; 1975 Oct; 46(4):543-53. PubMed ID: 126094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrin suspension as a substrate fop plasmin: determination and kinetics.
    Kanai S; Okamoto H; Tamaura Y; Yamazaki S; Inada Y
    Thromb Haemost; 1979 Dec; 42(4):1153-8. PubMed ID: 161668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.
    Harpel PC
    J Clin Invest; 1981 Jul; 68(1):46-55. PubMed ID: 6166634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of C1-esterase inhibitor and plasmin in human euglobulin.
    Highsmith RF; Burnett CJ; Weirich CJ
    J Lab Clin Med; 1979 Mar; 93(3):459-71. PubMed ID: 155127
    [No Abstract]   [Full Text] [Related]  

  • 7. [Index of fibrinolysis with new fibrin plate (author's transl)].
    Hishikawa Y; Sugie I
    Nihon Seirigaku Zasshi; 1977; 39(1):1-11. PubMed ID: 140239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-alpha 2-plasmin inhibitor complex in plasma.
    Takahashi H; Takizawa S; Hanano M; Tatewaki W; Nagasaki Y; Sasagawa Y; Shibata A
    Tohoku J Exp Med; 1987 Dec; 153(4):295-302. PubMed ID: 2964745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein.
    Binnema DJ; Dooijewaard G; Turion PN
    Thromb Haemost; 1991 Feb; 65(2):144-8. PubMed ID: 1905069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolysis in normal plasma and blood: evidence for significant mechanisms independent of the plasminogen-plasmin system.
    Moroz LA; Gilmore NJ
    Blood; 1976 Oct; 48(4):531-45. PubMed ID: 134751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmin potency estimates: influence of the substrate used in assay.
    Philo RD; Gaffney PJ
    Thromb Haemost; 1981 Apr; 45(2):107-9. PubMed ID: 6454987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolysis and thrombosis of fibrinogen-modified gold nanoparticles for detection of fibrinolytic-related proteins.
    Jian JW; Chiu WC; Chang HT; Hsu PH; Huang CC
    Anal Chim Acta; 2013 Apr; 774():67-72. PubMed ID: 23567118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell's viper venom.
    Cheng AC; Tsai IH
    Biochim Biophys Acta; 2014 Jan; 1840(1):153-9. PubMed ID: 23999090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of plasmin: a fibrinogenolytic method.
    Vukovich T
    Clin Chim Acta; 1977 Sep; 79(2):285-90. PubMed ID: 142589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
    Lind SE; Smith CJ
    Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
    Rouy D; Anglés-Cano E
    Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A delaying influence of cryoglobulins in the assessment of euglobulin fibrinolytic activity.
    Gram J; Jespersen J; Astrup T
    Thromb Res; 1986 Mar; 41(6):781-9. PubMed ID: 2422781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.